Scarica l'app Stockscreener
187.11
1.22%
2.26
Pre-mercato:
187.16
0.05
+0.03%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$184.85
Aprire:
$184.94
Volume 24 ore:
4.43M
Relative Volume:
0.66
Capitalizzazione di mercato:
$330.51B
Reddito:
$57.37B
Utile/perdita netta:
$4.20B
Rapporto P/E:
79.62
EPS:
2.35
Flusso di cassa netto:
$15.39B
1 W Prestazione:
+0.39%
1M Prestazione:
+0.98%
6M Prestazione:
+10.59%
1 anno Prestazione:
+7.78%
Intervallo 1D:
$184.90
$188.20
Intervallo di 1 settimana:
$184.63
$192.34
Portata 52W:
$163.81
$218.66
Abbvie Inc Stock (ABBV) Company Profile
Nome
Abbvie Inc
Settore
Industria
Telefono
(847) 932-7900
Indirizzo
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Confronta ABBV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
187.11 | 329.24B | 57.37B | 4.20B | 15.39B | 2.35 |
|
LLY
Lilly Eli Co
|
776.44 | 692.83B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
167.93 | 373.35B | 90.63B | 22.66B | 18.57B | 9.35 |
|
NVS
Novartis Ag Adr
|
116.83 | 231.66B | 55.19B | 13.65B | 16.81B | 6.86 |
|
NVO
Novo Nordisk Adr
|
66.78 | 298.68B | 43.59B | 15.04B | 10.74B | 3.3766 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-14 | Downgrade | Citigroup | Buy → Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-05 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-04 | Aggiornamento | Argus | Hold → Buy |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-06-05 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-05-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-12-11 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-30 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-07-25 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-04-05 | Downgrade | Argus | Buy → Hold |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2023-02-22 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-11-08 | Downgrade | Societe Generale | Buy → Hold |
| 2022-08-01 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Underperform |
| 2022-05-06 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-02-28 | Downgrade | UBS | Buy → Neutral |
| 2022-02-03 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-03 | Reiterato | Barclays | Equal Weight |
| 2022-02-03 | Reiterato | BofA Securities | Neutral |
| 2022-02-03 | Reiterato | Goldman | Neutral |
| 2022-01-13 | Iniziato | Redburn | Buy |
| 2022-01-12 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-11-23 | Aggiornamento | Societe Generale | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2020-11-10 | Ripresa | Bernstein | Outperform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-23 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Aggiornamento | Argus | Hold → Buy |
| 2020-05-18 | Ripresa | BofA/Merrill | Neutral |
| 2020-05-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Ripresa | Morgan Stanley | Overweight |
| 2020-04-20 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Reiterato | Cowen | Outperform |
| 2019-09-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-08-20 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Iniziato | Goldman | Neutral |
| 2019-04-29 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
Mostra tutto
Abbvie Inc Borsa (ABBV) Ultime notizie
AbbVie (ABBV) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Lip Fillers Market Is Booming So Rapidly 2025-2032Allergan (AbbVie Inc.), Galderma S.A., Merz Pharma - openPR.com
Why AbbVie (ABBV) is a Strong Buy for Diversified Portfolios in a Volatile Market - AInvest
4 Reasons To Buy AbbVie (NYSE:ABBV) - Seeking Alpha
IGI, Abbvie team up to advance myeloma treatment ISB 2001 - Rare Cancer News
BOTOX® Cosmetic (onabotulinumtoxinA) Selects This Year's Entrepreneurs for The Confidence Project - AbbVie News Center
2 High-Yield Dividend ETFs That Could Deliver Steady Income for Decades - The Motley Fool
Lobbying Update: $1,160,000 of ABBVIE INC. lobbying was just disclosed - Quiver Quantitative
AbbVie's Allergan wins $56 million in Botox patent fight - Crain's Chicago Business
AbbVie unit wins $56 mln in US patent trial against Botox rival - Reuters
AbbVie Unit Wins $56 Million from Revance Over Botox Patents (1) - Bloomberg Law News
Stacey McCullough: I’m Thrilled to Join AbbVie Oncology Working in Market Access - Oncodaily
How Will AbbVie's Neuroscience Franchise Perform In Q2 Earnings? - Barchart.com
Non-Small Cell Lung Cancer Pipeline 2025: In-depth Clinical Trials Analysis and Emerging Therapies Report by DelveInsight | AbbVie, Xcovery, Sanofi, Pfizer, Mirati Therapeutics, AstraZeneca - Barchart.com
What drives AbbVie Inc. stock priceFree Technical Analysis Support - printweek.in
AbbVie's Q1 2025 Earnings Surge 6.5% Year-Over-Year - AInvest
Is AbbVie Inc. a good long term investmentMassive stock growth - printweek.in
What analysts say about AbbVie Inc. stockConsistently superior profits - Autocar Professional
AbbVie Stock (ABBV) Opinions on Recent Price Surge and Sales Growth - Quiver Quantitative
Morgan Stanley Reiterates a Buy Rating on AbbVie (ABBV) With a $250 PT - MSN
AbbVie Inc. Stock Analysis and ForecastExceptional profit margins - PrintWeekIndia
AbbVie’s Phase 3 Study on Atogepant: A Potential Game-Changer for Pediatric Migraine Prevention - TipRanks
Why AbbVie (ABBV) Remains a Dividend Standout in the Pharma Sector - MSN
Rothschild Raises AbbVie (ABBV) Price Target, Maintains Buy Rating - MSN
AbbVie Inc. stock underperforms Friday when compared to competitors - MarketWatch
AbbVie’s Real-World Study on Upadacitinib for Atopic Dermatitis: Key Insights for Investors - TipRanks
AbbVie and Genmab’s Epcoritamab Trial: A Potential Game-Changer for B-NHL Treatment - TipRanks
AbbVie’s Observational Study on Upadacitinib: A Boost for Adolescent Atopic Dermatitis Treatment - TipRanks
AbbVie’s Pediatric Ulcerative Colitis Study: A Potential Game-Changer? - TipRanks
AbbVie’s Upadacitinib Study: A New Hope for Hidradenitis Suppurativa? - TipRanks
AbbVie’s Venetoclax Study Update: Long-Term Safety in Focus - TipRanks
AbbVie’s Long-term Study on Bimatoprost SR: A Potential Game-Changer in Glaucoma Treatment - TipRanks
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Why AbbVie Is a Strong Buy for Long-Term Investors in 2025 - FXEmpire
AbbVie’s Rinvoq Study in Japan: A Closer Look at Ulcerative Colitis Treatment - TipRanks
Glenmark Pharma, a BSE 500 stock, has rallied 34% in 1 month! AbbVie's licensing deal a big positive - Upstox
Here's How to Play AbbVie Stock as it Reaches Golden Cross - MSN
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Glenmark Pharma Will Turn Cash Positive With AbbVies Licensing Deal: S&P - NDTV Profit
AbbVie’s New Study on Crohn’s Disease Therapies: A Potential Game Changer? - TipRanks
AbbVie’s New Study on CLL Treatments: Market Implications and Investor Insights - TipRanks
AbbVie’s Oriahnn Study: Evaluating Hair Loss in Women with Uterine Fibroids - TipRanks
AbbVie’s Ubrogepant Study: A New Hope for Menstrual Migraine Relief - TipRanks
AbbVie’s Venetoclax Study in Greece: A Closer Look at CLL Treatment Outcomes - TipRanks
AbbVie’s Real-World Study on Upadacitinib for Crohn’s Disease: Key Insights for Investors - TipRanks
Abbvie Inc Azioni (ABBV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):